Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Genes Chromosomes Cancer. 2018 Oct;57(10):525-529. doi: 10.1002/gcc.22648. Epub 2018 Aug 20.
Clear cell sarcoma of the kidney (CCSK) is the second most common renal malignancy in children. The prognosis is poorer in CCSK than in Wilms' tumor, and multimodal treatment including surgery, intensive chemotherapy, and radiation is required to improve the outcome for children with CCSK. Histological evaluation is required for the diagnosis. However, biopsies of tumors to obtain diagnostic specimens are not routinely performed because of the risk of spreading tumor cells during the procedure. Recently, internal tandem duplication (ITD) of BCOR has been recognized as a genetic hallmark of CCSK. We herein established a novel BCOR-ITD-specific polymerase chain reaction method with well-designed primers, and then performed a liquid biopsy for cell-free DNA (cfDNA) obtained from plasma of three children with nonmetastatic renal tumors (stage II) and from one control. BCOR-ITD was positively detected in the cfDNA of two cases, both of which were later diagnosed as CCSK based on histological feature of the resected tumor specimen, while it was not detected for a normal control and a patient diagnosed with Wilms' tumor. Our study is the first one of preoperative circulating tumor DNA assay in pediatric renal tumors. The liquid biopsy method enables less invasive, preoperative diagnosis of CCSK with no risk of tumor spillage, which can avoid iatrogenic upstaging.
肾透明细胞肉瘤(CCSK)是儿童中第二常见的肾恶性肿瘤。CCSK 的预后比 Wilms 瘤差,需要多模式治疗,包括手术、强化化疗和放疗,以改善 CCSK 患儿的预后。组织学评估是诊断所必需的。然而,由于在手术过程中存在肿瘤细胞扩散的风险,通常不进行肿瘤活检以获取诊断标本。最近,BCOR 的内部串联重复(ITD)已被认为是 CCSK 的遗传标志。我们在此建立了一种新的 BCOR-ITD 特异性聚合酶链反应方法,使用精心设计的引物,然后对来自三名非转移性肾肿瘤(II 期)患儿和一名对照患儿血浆中游离细胞 DNA(cfDNA)进行液体活检。在两个病例的 cfDNA 中均检测到 BCOR-ITD 阳性,这两个病例后来根据切除肿瘤标本的组织学特征诊断为 CCSK,而正常对照和诊断为 Wilms 瘤的患者未检测到 BCOR-ITD。我们的研究是首例儿童肾肿瘤术前循环肿瘤 DNA 检测。该液体活检方法可进行微创、术前诊断 CCSK,无肿瘤播散风险,可避免医源性分期升级。